177 related articles for article (PubMed ID: 21739122)
1. Immunotherapy response evaluation with (18)F-FDG-PET in patients with advanced stage renal cell carcinoma.
Gilles R; de Geus-Oei LF; Mulders PF; Oyen WJ
World J Urol; 2013 Aug; 31(4):841-6. PubMed ID: 21739122
[TBL] [Abstract][Full Text] [Related]
2. A prospective diagnostic accuracy study of F-18 fluorodeoxyglucose-positron emission tomography/computed tomography in the evaluation of indeterminate renal masses.
Ozülker T; Ozülker F; Ozbek E; Ozpaçaci T
Nucl Med Commun; 2011 Apr; 32(4):265-72. PubMed ID: 21301376
[TBL] [Abstract][Full Text] [Related]
3. Positron emission tomography for prostate, bladder, and renal cancer.
Schöder H; Larson SM
Semin Nucl Med; 2004 Oct; 34(4):274-92. PubMed ID: 15493005
[TBL] [Abstract][Full Text] [Related]
4. Recurrent renal cell carcinoma: clinical and prognostic value of FDG PET/CT.
Alongi P; Picchio M; Zattoni F; Spallino M; Gianolli L; Saladini G; Evangelista L
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):464-73. PubMed ID: 26268680
[TBL] [Abstract][Full Text] [Related]
5. Role of Positron Emission Tomography Imaging in Metabolically Active Renal Cell Carcinoma.
Karivedu V; Jain AL; Eluvathingal TJ; Sidana A
Curr Urol Rep; 2019 Aug; 20(10):56. PubMed ID: 31468240
[TBL] [Abstract][Full Text] [Related]
6. Significance of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography for the postoperative surveillance of advanced renal cell carcinoma.
Park JW; Jo MK; Lee HM
BJU Int; 2009 Mar; 103(5):615-9. PubMed ID: 19007371
[TBL] [Abstract][Full Text] [Related]
7. PET scans for decision-making in metastatic renal cell carcinoma: a single-institution evaluation.
Dilhuydy MS; Durieux A; Pariente A; de Clermont H; Pasticier G; Monteil J; Ravaud A
Oncology; 2006; 70(5):339-44. PubMed ID: 17164590
[TBL] [Abstract][Full Text] [Related]
8. The acceleration of glucose accumulation in renal cell carcinoma assessed by FDG PET/CT demonstrated acquisition of resistance to tyrosine kinase inhibitor therapy.
Nakaigawa N; Kondo K; Ueno D; Namura K; Makiyama K; Kobayashi K; Shioi K; Ikeda I; Kishida T; Kaneta T; Minamimoto R; Tateishi U; Inoue T; Yao M
BMC Cancer; 2017 Jan; 17(1):39. PubMed ID: 28068944
[TBL] [Abstract][Full Text] [Related]
9. FDG PET/CT after first molecular targeted therapy predicts survival of patients with renal cell carcinoma.
Nakaigawa N; Kondo K; Kaneta T; Tateishi U; Minamimoto R; Namura K; Ueno D; Kobayashi K; Kishida T; Ikeda I; Hasumi H; Makiyama K; Hayashi N; Osaka K; Muraoka K; Izumi K; Kawahara T; Teranishi JI; Miyoshi Y; Yumura Y; Uemura H; Inoue T; Yao M
Cancer Chemother Pharmacol; 2018 Apr; 81(4):739-744. PubMed ID: 29464355
[TBL] [Abstract][Full Text] [Related]
10. F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma.
Majhail NS; Urbain JL; Albani JM; Kanvinde MH; Rice TW; Novick AC; Mekhail TM; Olencki TE; Elson P; Bukowski RM
J Clin Oncol; 2003 Nov; 21(21):3995-4000. PubMed ID: 14581422
[TBL] [Abstract][Full Text] [Related]
11. One-month assessment of renal cell carcinoma treated by everolimus using FDG PET/CT predicts progression-free and overall survival.
Ito H; Kondo K; Kawahara T; Kaneta T; Tateishi U; Ueno D; Namura K; Kobayashi K; Miyoshi Y; Yumura Y; Makiyama K; Hayashi N; Hasumi H; Osaka K; Yokomizo Y; Teranishi JI; Hattori Y; Inoue T; Uemura H; Yao M; Nakaigawa N
Cancer Chemother Pharmacol; 2017 May; 79(5):855-861. PubMed ID: 28331985
[TBL] [Abstract][Full Text] [Related]
12. F-18 FDG PET in detecting renal cell carcinoma.
Ak I; Can C
Acta Radiol; 2005 Dec; 46(8):895-9. PubMed ID: 16392617
[TBL] [Abstract][Full Text] [Related]
13. 18F-FDG-PET/CT in potentially advanced renal cell carcinoma: a role in treatment decisions and prognosis estimation.
Ferda J; Ferdova E; Hora M; Hes O; Finek J; Topolcan O; Kreuzberg B
Anticancer Res; 2013 Jun; 33(6):2665-72. PubMed ID: 23749925
[TBL] [Abstract][Full Text] [Related]
14. Restaging clear cell renal carcinoma with 18F-FDG PET/CT.
Fuccio C; Ceci F; Castellucci P; Spinapolice EG; Palumbo R; D'Ambrosio D; Bernardo A; Brunocilla E; Schiavina R; Maffione AM; Chondrogiannis S; Grassetto G; Colletti PM; Rubello D; Fanti S; Trifirò G
Clin Nucl Med; 2014 Jun; 39(6):e320-4. PubMed ID: 24566409
[TBL] [Abstract][Full Text] [Related]
15. Clinical utility of
Nakamoto Y; Ishimori T; Shimizu Y; Sano K; Togashi K
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1524-1530. PubMed ID: 30847538
[TBL] [Abstract][Full Text] [Related]
16. 18F-FDG PET/CT imaging for an early assessment of response to sunitinib in metastatic renal carcinoma: preliminary study.
Vercellino L; Bousquet G; Baillet G; Barré E; Mathieu O; Just PA; Desgrandchamps F; Misset JL; Hindié E; Moretti JL
Cancer Biother Radiopharm; 2009 Feb; 24(1):137-44. PubMed ID: 19243256
[TBL] [Abstract][Full Text] [Related]
17. Clinical utility of FDG PET/CT for primary and recurrent papillary renal cell carcinoma.
Hou G; Zhao D; Jiang Y; Zhu Z; Huo L; Li F; Cheng W
Cancer Imaging; 2021 Feb; 21(1):25. PubMed ID: 33632314
[TBL] [Abstract][Full Text] [Related]
18. Metastatic Renal Cell Cancer Treated With Antiangiogenic Therapy Monitoring by 18F-FDG PET/CT.
García Garzon JR; Bassa P; Llinares E; Soler M; Moragas M; Riera E
Clin Nucl Med; 2015 Nov; 40(11):910-1. PubMed ID: 26252325
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic role of [F-18]-FDG positron emission tomography in restaging renal cell carcinoma.
Jadvar H; Kherbache HM; Pinski JK; Conti PS
Clin Nephrol; 2003 Dec; 60(6):395-400. PubMed ID: 14690256
[TBL] [Abstract][Full Text] [Related]
20. Clinical role of early dynamic FDG-PET/CT for the evaluation of renal cell carcinoma.
Nakajima R; Abe K; Kondo T; Tanabe K; Sakai S
Eur Radiol; 2016 Jun; 26(6):1852-62. PubMed ID: 26403580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]